For instance, a Phase 1/2 clinical trial (BRILLIANCE) is evaluating the safety and efficacy of EDIT-101, a CRISPR/Cas9-based therapy targeting the CEP290 mutation associated with Leber Congenital Amaurosis 10 (LCA10). The gene discussed is CEP290; the disease is Leber congenital amaurosis 10.